about
Managing Inflammatory Manifestations in Patients with Chronic Granulomatous Disease.Gene Therapy in a Patient with Sickle Cell Disease.Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1.Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells.Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS).Evaluation of the power of six clustering features in identifying a homogeneous disease subset in juvenile idiopathic arthritis (JIA).Plerixafor enables the safe, rapid, efficient mobilization of haematopoietic stem cells in sickle cell disease patients after exchange transfusion.Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous diseaseSuccessful in utero stem cell transplantation in X-linked severe combined immunodeficiencySuccessful haematopoietic stem cell transplantation in a case of pulmonary alveolar proteinosis due to GM-CSF receptor deficiencyModalités de préparation, cryopréservation, décongélation des cellules souches hématopoïétiques et précautions pour infusion au patient : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritisAchievement of a State of Inactive Disease at Least Once in the First 5 Years Predicts Better Outcome of Patients with Polyarticular Juvenile Idiopathic ArthritisImpact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritisThe magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritisClonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs
P50
Q39684886-DB772FDA-07C5-41CB-BC0E-B3EA4352B629Q40313066-084FEACD-805F-4C98-8036-ED520E5D0B20Q41079369-66F04592-0FCD-4642-98E4-92FAB7475F6EQ44748373-95A485A4-C063-4175-BB33-F728A0F7617FQ45744212-71C0461A-98FE-40BC-956F-A2412E0D40CFQ45745820-A7C8B7AC-4BF2-49F9-9FB6-D3FD8E6A809EQ50145999-D0B78410-6905-43AE-9262-D8A338852026Q57216992-CC4C6BA9-8DCE-4810-828A-4C549292D09CQ61808823-10F9415B-3211-4C04-9F11-D0A231BD7AA0Q62741369-36215E95-E8CD-4F90-8297-F244144EBD54Q62741392-DC20228D-D967-4531-A897-3BB587068579Q62741431-B247CFCE-0790-4072-9699-95F3FA35D193Q62741443-99DE5785-3E95-4EFE-8B53-2D570175BE2CQ62741456-312479D1-C486-4025-88B3-3672CBFE25CAQ62741468-6084821B-3AC0-447F-A1AB-FA447C7EE818Q89629374-FD8E060B-CD40-4CEB-B817-5C7444A4C788
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alessandra Magnani
@ast
Alessandra Magnani
@en
Alessandra Magnani
@es
Alessandra Magnani
@nl
type
label
Alessandra Magnani
@ast
Alessandra Magnani
@en
Alessandra Magnani
@es
Alessandra Magnani
@nl
prefLabel
Alessandra Magnani
@ast
Alessandra Magnani
@en
Alessandra Magnani
@es
Alessandra Magnani
@nl
P1053
H-8231-2017
P106
P1153
23569650300
P21
P31
P3829
P496
0000-0002-0674-9288